Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS EBIT

EBIT at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
——
Merck & Co. logo
Merck & Co.MRK
——
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——
AbbVie logo
AbbVieABBV
——

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Calculated from Arcus Biosciences’s reported figures.

−$134.0Moperating income−$128.0Mincome before tax+$3.0Minterest expense=-$134M

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's EBIT?
Arcus Biosciences (RCUS) reported EBIT of -$134M in Q1 2026.
How has Arcus Biosciences's EBIT changed year-over-year?
Arcus Biosciences's EBIT decreased by 9.8% year-over-year, from -$122M to -$134M.
What is the long-term trend for Arcus Biosciences's EBIT?
Over 4 years (2021 to 2025), Arcus Biosciences's EBIT has grown at a 63.5% compound annual growth rate (CAGR), from $54M to -$386M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.